康乃德生物医药宣布,其核心候选药物Rademikibart针对中重度特应性皮炎的III期临床试验数据,已获选将于2026年美国皮肤病学会年会的最新突破性研究环节中进行公布。这一环节专门用于展示具有重大临床意义的突破性研究成果,标志着该研究数据的重要性得到了国际顶级学术会议的高度认可。
康乃德生物医药宣布,其核心候选药物Rademikibart针对中重度特应性皮炎的III期临床试验数据,已获选将于2026年美国皮肤病学会年会的最新突破性研究环节中进行公布。这一环节专门用于展示具有重大临床意义的突破性研究成果,标志着该研究数据的重要性得到了国际顶级学术会议的高度认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.